Euroapi S.A. (EAPI.PA)
Paris · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€0.816 (+3.03%) as of
Key statistics
- Market cap
- 77.95M
- Forward P/E
- -3.82
- EPS (TTM)
- -3.4200
- Dividend yield
- 0.00%
- 52-week range
- 0.7130 – 3.3880
- Beta
- 1.01
- Revenue (TTM)
- 794.6M
- Profit margin
- -40.80%
- Analyst target
- €1.00
- Volume
- 265.56k
About Euroapi S.A.
Euroapi S.A. develops, manufactures, markets, and distributes active pharmaceutical ingredients and intermediates used in the formulation of medicines for human and veterinary use in France, Europe, Rest of Europe, North America, the Asia Pacific, and internationally. The company offers contract development manufacturing organization for different classes of tides that use solid phase chemistry; particle engineering; microbial fermentation; small molecules synthesis; prostaglandins; and steroids and hormones substances. It also provides API solutions, such as vitamin B12, prostaglandins, corticoids and hormones, anti-infectives, opiates and controlled substances, small and complex molecules, and intermediates and reagents. It sells their products to laboratories in the pharmaceutical industry, manufacturers of generic drug and animal health products, consumer health companies, nutrition companies, cosmetics companies, biotechnology companies, contract development and manufacturing organizations. Euroapi S.A. was incorporated in 2020 and is based in Paris, France.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Paris, France
- Employees
- 3,000
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.